ACDF Brief comments: What has changed significantly in evaluating and considering CV risk in managing patients with diabetes?1
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- Asian Cardio Diabetes Forum 2019ACDF Brief comments: The evolving role of SGLT2 inhibitors in heart failure?
- Asian Cardio Diabetes Forum 2019Lecture: Cardiovascular outcomes that will change diabetes practice: What are the key findings from recent trials
Prof. Mark Cooper, MD
- Asian Cardio Diabetes Forum 2019Lecture: The Kidney: Opportunities for protection and prevention
- Asian Cardio Diabetes Forum 2019Lecture: Heart Failure: The next frontier for SGLT2 inhibitors?
Prof. Nikolaus Marx, MD